Scholarlink

Background <p>Glioblastoma (GBM), the most aggressive adult brain tumor, remains a significant clinical challenge. Pyruvate kinase M2 (PKM2), by shifting between its tetrameric (metabolic) and dimeric (oncogenic) forms, drives GBM metabolism and tumorigenesis, regulating the Warburg effect. This study explores a drug repurposing strategy to identify clinically approved medications capable of stabilizing PKM2 in its tetrameric form, thus disrupting GBM metabolic adaptability and oncogenic potential.</p> Methods <p>We employed a multi-step screening strategy that integrates virtual screening, pharmacological data analysis, and in vitro cellular assays performed on anchorage-dependent and -independent GBM cell lines. This methodological process highlights the potential of repurposable drugs to target a cancer-specific metabolic vulnerability, thereby accelerating the development of novel therapeutic strategies for GBM.</p> Results <p>From thousands of clinically approved drugs, we selected, among those potentially able to cross the blood-brain barrier, three candidates that significantly inhibited GBM cell viability, reduced PKM2 nuclear localization, and impaired glycolytic activity, suggesting their potential to attenuate the Warburg effect and tumor malignancy.</p> Conclusions <p>We established a detailed screening protocol for drug repurposing to treat GBM. This approach targets a critical vulnerability of GBM cells by disrupting their bioenergetic balance. Since metabolic reprogramming and the associated Warburg effect are hallmarks of many cancers, not just GBM, we believe this approach holds significant potential for use against a wider range of tumors.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated screening for small molecules interfering with PKM2: a drug repurposing strategy against glioblastoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月8日

查看全文
  • Susan Costantini,
  • Isabella Romeo,
  • Giulia Fanelli,
  • Maria Serena Roca,
  • Gianmarco Gualtieri,
  • Palmina Bagnara,
  • Andrea Polo,
  • Elena Di Gennaro,
  • Francesco Ortuso,
  • Stefano Alcaro,
  • Alfredo Budillon,
  • Gennaro Ciliberto,
  • Marco G. Paggi,
  • Claudia Abbruzzese

摘要

Background

Glioblastoma (GBM), the most aggressive adult brain tumor, remains a significant clinical challenge. Pyruvate kinase M2 (PKM2), by shifting between its tetrameric (metabolic) and dimeric (oncogenic) forms, drives GBM metabolism and tumorigenesis, regulating the Warburg effect. This study explores a drug repurposing strategy to identify clinically approved medications capable of stabilizing PKM2 in its tetrameric form, thus disrupting GBM metabolic adaptability and oncogenic potential.

Methods

We employed a multi-step screening strategy that integrates virtual screening, pharmacological data analysis, and in vitro cellular assays performed on anchorage-dependent and -independent GBM cell lines. This methodological process highlights the potential of repurposable drugs to target a cancer-specific metabolic vulnerability, thereby accelerating the development of novel therapeutic strategies for GBM.

Results

From thousands of clinically approved drugs, we selected, among those potentially able to cross the blood-brain barrier, three candidates that significantly inhibited GBM cell viability, reduced PKM2 nuclear localization, and impaired glycolytic activity, suggesting their potential to attenuate the Warburg effect and tumor malignancy.

Conclusions

We established a detailed screening protocol for drug repurposing to treat GBM. This approach targets a critical vulnerability of GBM cells by disrupting their bioenergetic balance. Since metabolic reprogramming and the associated Warburg effect are hallmarks of many cancers, not just GBM, we believe this approach holds significant potential for use against a wider range of tumors.

Graphical Abstract